Kinaxo Collaborates with Roche in the Field of Phosphoproteomics

Kinaxo Biotechnologies has entered into a collaboration with Roche Diagnostics in Penzberg, Germany. Under the agreement, the former’s phosphoproteomics technology PhosphoScout will be applied to support the identification of biomarkers that are related to new treatment approaches based on therapeutic antibodies currently under development at Roche. Financial details of the agreement were not disclosed.

Dr Klaus Godl, CSO, Kinaxo commented: “Cellular signal transmission in eukaryotic cells is mainly regulated by the reversible phosphorylation of proteins. Therefore, the differential analysis of the complete cellular phosphoproteome upon drug treatment provides informative insights into the modes of action of targeted cancer drugs.”